Institutional members access full text with Ovid®

Share this article on:

Trough Concentrations of Vancomycin: Adult Therapeutic Targets Are Not Appropriate for Children

Gordon, Claire L. MB BS, BMedSci*; Thompson, Chantelle BPharm; Carapetis, Jonathan R. MB BS, PhD*‡§¶; Turnidge, John MB BS, PhD║**; Kilburn, Charles MB BS; Currie, Bart J. MB BS, PhD*‡

The Pediatric Infectious Disease Journal: December 2012 - Volume 31 - Issue 12 - p 1269–1271
doi: 10.1097/INF.0b013e31826a3eaf
Antimicrobial Review

Despite the need for effective vancomycin therapy, there are few data guiding vancomycin monitoring in children. We reviewed retrospectively vancomycin use in children 1 month to 12 years of age. Initial and adjusted target trough vancomycin concentrations in serum were infrequently achieved regardless of the dosing schedule. Currently recommended trough concentrations need to be re-examined with a more detailed pharmacokinetic study in children.

Supplemental Digital Content is available in the text.

From the *Departments of Infectious Diseases and Pharmacy, Royal Darwin Hospital; Menzies School of Health Research; and §Department of Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia; Telethon Institute for Child Health Research and University of Western Australia, Perth, Western Australia; SA Pathology, Women’s and Children’s Hospital, Adelaide, South Australia, Australia; and **University of Adelaide, Adelaide, South Australia, Australia.

Accepted for publication July 17, 2012.

CLG and CT contributed equally to this article.

The authors have no conflicts of interest or funding to disclose.

Address for correspondence: Claire L. Gordon, MBBS, BMedSci, Department of Infectious Diseases, Royal Darwin Hospital, 105 Rocklands Drive, Tiwi NT 0810, Australia. E-mail:

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (

© 2012 Lippincott Williams & Wilkins, Inc.